Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shaji Kumar

Showing results (211-220 of 516) with videos related to

Pageof 52
Sort By:
JCO Oncology Practice|February 9, 2023
Clinical Administration Characteristics of Subcutaneous and Intravenous Administration of Daratumumab in Patients With Multiple Myeloma at Mayo Clinic Infusion CentersScott A Soefje, Corinne Carpenter, Katherine Carlson, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 24, 2011
Differential cytopathology and kinetics of measles oncolysis in two primary B-cell malignancies provides mechanistic insightsBella Patel, Aditi Dey, Ehsan Ghorani, et al.
Mayo Clinic Proceedings|January 7, 2018
Safety Outcomes for Autologous Stem Cell Transplant in Multiple MyelomaMorie A Gertz, Francis K Buadi, Suzanne R Hayman, et al.
Advances in Therapy|March 5, 2022
Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysisThierry Facon, Jesús San-Miguel, Meletios A Dimopoulos, et al.
Transplantation and Cellular Therapy|June 21, 2021
The Efficacy and Safety of Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma Patients Who Are Poor Responders to Induction: The Mayo Clinic ExperienceIuliana Vaxman, Eli Muchtar, Eapen Jacob, et al.
American Journal of Hematology|June 1, 2010
Serum immunoglobulin free light chain measurements and heavy chain isotype usage provide insight into disease biology in patients with POEMS syndromeTrista Stankowski-Drengler, Morie A Gertz, Jerry A Katzmann, et al.
American Journal of Hematology|October 17, 2020
Outcomes of multiple myeloma patients with del 17p undergoing autologous stem cell transplantationIuliana Vaxman, Alissa Visram, Prashant Kapoor, et al.
American Journal of Hematology|August 29, 2025
Real-World Outcomes of Transplant Ineligible Older Adults With Multiple Myeloma Treated With Novel Regimens: A Population-Based Retrospective Cohort StudyNadine Abdallah, Hira Mian, Hsien Seow, et al.
Journal of the American Society of Nephrology : JASN|April 23, 2011
Early reduction of serum-free light chains associates with renal recovery in myeloma kidneyColin A Hutchison, Paul Cockwell, Stephanie Stringer, et al.
Cancer Research|January 7, 2006
Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cellsAldo Maria Roccaro, Teru Hideshima, Noopur Raje, et al.
Pageof 52

Showing results (211-220 of 516) with videos related to

Sort By:
Pageof 52
JCO Oncology Practice|February 9, 2023
Clinical Administration Characteristics of Subcutaneous and Intravenous Administration of Daratumumab in Patients With Multiple Myeloma at Mayo Clinic Infusion CentersScott A Soefje, Corinne Carpenter, Katherine Carlson, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 24, 2011
Differential cytopathology and kinetics of measles oncolysis in two primary B-cell malignancies provides mechanistic insightsBella Patel, Aditi Dey, Ehsan Ghorani, et al.
Mayo Clinic Proceedings|January 7, 2018
Safety Outcomes for Autologous Stem Cell Transplant in Multiple MyelomaMorie A Gertz, Francis K Buadi, Suzanne R Hayman, et al.
Advances in Therapy|March 5, 2022
Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysisThierry Facon, Jesús San-Miguel, Meletios A Dimopoulos, et al.
Transplantation and Cellular Therapy|June 21, 2021
The Efficacy and Safety of Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma Patients Who Are Poor Responders to Induction: The Mayo Clinic ExperienceIuliana Vaxman, Eli Muchtar, Eapen Jacob, et al.
American Journal of Hematology|June 1, 2010
Serum immunoglobulin free light chain measurements and heavy chain isotype usage provide insight into disease biology in patients with POEMS syndromeTrista Stankowski-Drengler, Morie A Gertz, Jerry A Katzmann, et al.
American Journal of Hematology|October 17, 2020
Outcomes of multiple myeloma patients with del 17p undergoing autologous stem cell transplantationIuliana Vaxman, Alissa Visram, Prashant Kapoor, et al.
American Journal of Hematology|August 29, 2025
Real-World Outcomes of Transplant Ineligible Older Adults With Multiple Myeloma Treated With Novel Regimens: A Population-Based Retrospective Cohort StudyNadine Abdallah, Hira Mian, Hsien Seow, et al.
Journal of the American Society of Nephrology : JASN|April 23, 2011
Early reduction of serum-free light chains associates with renal recovery in myeloma kidneyColin A Hutchison, Paul Cockwell, Stephanie Stringer, et al.
Cancer Research|January 7, 2006
Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cellsAldo Maria Roccaro, Teru Hideshima, Noopur Raje, et al.
Pageof 52